3月5日 - ** 制药商库拉肿瘤KURA.O股价盘前下跌5.80%至8.05美元
** 根据LSEG汇编的数据，该公司第四季度每股亏损92美分，而分析师预期为每股亏损61美分。
** 第四季度营收为1730万美元，低于分析师预计的5360万美元
** 本季度的研发费用为6440万美元，主要用于推进其血癌药物ziftomenib - KURA的联合试验。
** 2025年KURA股价上涨了19%以上
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.